Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C136987
http://purl.obolibrary.org/obo/NCIT_C136987
|
|---|---|
| Preferred Name | Patritumab Deruxtecan |
| Definitions |
An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),linked to the topoisomerase I inhibitor DX 8951, a semisynthetic, water-soluble derivative of camptothecin, with potential antineoplastic activity. Upon administration of patritumab deruxtecan, the patritumab moiety targets and binds to HER3. After internalization, DX 8951 inhibits topoisomerase I activity by stabilizing the complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),linked to the topoisomerase I inhibitor DX 8951, a semisynthetic, water-soluble derivative of camptothecin, with potential antineoplastic activity. Upon administration of patritumab deruxtecan, the patritumab moiety targets and binds to HER3. After internalization, DX 8951 inhibits topoisomerase I activity by stabilizing the complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors. |
|---|---|
| prefLabel | Patritumab Deruxtecan
|
| label | Patritumab Deruxtecan
|
| NCI_META_CUI | CL524745
|
| PDQ_Closed_Trial_Search_ID | 789807
|
| code | C136987
|
| Has_Target | |
| prefixIRI | NCIT:C136987
|
| in_subset |
See more
See less
|
| Display_Name | Patritumab Deruxtecan
|
| Preferred_Name | Patritumab Deruxtecan
|
| FDA_UNII_Code | 3XPI7EG4W8
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To |
Patritumab Deruxtecan
Anti-HER3 Antibody-drug Conjugate U3 1402
|
| CAS_Registry | 2227102-46-5
|
| NCI_Drug_Dictionary_ID | 789807
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 789807
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |